Randomised, Double-Blind, Placebo Controlled, Cross Over Trial of a Parenteral Modified Cobratoxin in Adrenomyeloneuropathy

INTERVENTION: Modified cobratoxin (0.25 mg) administered subcutaneously (sc) twice daily for 6 months versus placebo injections. CONDITION: Adrenomyeloneuropathy (AMN) ; Nervous System Diseases PRIMARY OUTCOME: Not provided at time of registration. ; SECONDARY OUTCOME: Not provided at time of registration. ; INCLUSION CRITERIA: 1. Male or female age =18 years 2. Diagnosis of AMN either biochemically or genetically 3. Have some motor disability that affects their gait 4. Willing and able to provide written informed consent 5. Willing and able to comply with study procedures